AURINIA PHARMACEUTICALS INC (AUPH)

This biopharma firm, focused on therapies for autoimmune diseases, reported a recent insider buy amid a year of strong share performance.

Arnab Paul·StocktwitsPublished May 07, 2026 | 1:55 PM EDT ... First-quarter revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease. The biotech firm reiterated its FY2026 revenue guidance of $315 millio…

Aurinia Pharmaceuticals director Craig A. Johnson receives 23,931 stock options at a $15.67 exercise price, vesting in one year and expiring June 4, 2036.

Director Tina Susan Nova receives 23,931 Aurinia stock options at a $15.67 exercise price, vesting after one year and expiring June 4, 2036, as compensation.

Kevin Tang–associated funds bought 814,606 Aurinia shares near $15 and sold 10,000 short puts, adding potential obligation to buy 1,000,000 more shares at $15 by Jan 15, 2027.